Levodopa/carbidopa/entacapone - Orion

Drug Profile

Levodopa/carbidopa/entacapone - Orion

Alternative Names: ODM-101

Latest Information Update: 31 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Orion
  • Class Antiparkinsonians; Catecholamines; Catechols; Hydrazines; Nitriles; Small molecules
  • Mechanism of Action Catechol-O-methyltransferase inhibitors; Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 21 Mar 2013 Efficacy & adverse events data from a phase II trial in Parkinson's disease presented at the 65th Annual Meeting of the American Academy of Neurology (AAN-2013)
  • 24 Oct 2012 Levodopa/carbidopa/entacapone - Orion is available for licensing as of 30 Sep 2012. http://www.orion.fi/
  • 23 Oct 2012 Efficacy data from a phase II trial in Parkinson's disease released by Orion
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top